Innovators of Coronary Angioplasty Win 2019 Fritz J. and Dolores H. Russ Prize
The National Academy of Engineering and Ohio University announced today that the 2019 Fritz J. and Dolores H. Russ Prize will be given to Julio Palmaz, Leonard Pinchuk, John Simpson, Richard Schatz, and Paul Yock for innovations leading to the widespread adoption of percutaneous coronary intervention (PCI), previously known as angioplasty with stent or coronary angioplasty. The $500,000 biennial prize, which recognizes a bioengineering achievement that significantly improves the human condition, cites PCI for"seminal contributions to coronary angioplasty, enabling minimally invasive treatment of advanced coronary art...
Source: News from the National Academies - January 3, 2019 Category: Science Source Type: news

Volumes Low for Unprotected Left Main PCI
WEDNESDAY, Jan. 2, 2019 -- Unprotected left main (ULM) percutaneous coronary intervention (PCI) procedures represented less than 1 percent of all PCIs in clinical practice in the United States from 2009 through 2016, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 2, 2019 Category: Pharmaceuticals Source Type: news

CathWorks wins FDA 510(k) for FFRangio
Non-invasive fractional flow reserve tech developer CathWorks said yesterday that it won FDA 510(k) clearance for its FFRangio non-invasive fractional flow reserve analysis technology. The Israel-based company said that approval came based off of results from the FAST-FFR blinded comparative study study which showed that its FFRangio system was accurate when compared to invasive FFR. “The FDA clearance of CathWorks FFRangio is a significant milestone for interventional cardiologists and the healthcare system overall. It is the first non-invasive device of its kind to receive FDA clearance for use during percutaneou...
Source: Mass Device - December 21, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Diagnostics Food & Drug Administration (FDA) Regulatory/Compliance Vascular cathworks Source Type: news

Upcoding Likely Used to Justify Inappropriate PCI Upcoding Likely Used to Justify Inappropriate PCI
Upcoding of stable chest pain to a diagnosis of unstable angina is likely being used to justify outpatient percutaneous coronary intervention (PCI) that would otherwise be deemed inappropriate, researchers report.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 20, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Clinical Performance Measures that Matter —Are You Ready?
Conclusion The future will belong to those who can prove value. The use of a clinical performance dashboard and comparisons to national data will help to ensure that when the payers come knocking on our doors looking for "proof" that what we do enhances patient care and improves patient outcome, we’ll have an answer! This is the first in a yearlong series of articles developed by the Academy of International Mobile Healthcare Integration (AIMHI).The AIMHI article series is developed in partnership with JEMS to help educate EMS agencies on the hallmarks and attributes of high-performance/high-value EMS system de...
Source: JEMS Special Topics - December 11, 2018 Category: Emergency Medicine Authors: Wayne C. Harbour, NRP Tags: Exclusive Articles Operations Administration and Leadership Source Type: news

Corindus touts first-in-human coronary telerobotics study with CorPath system
Corindus Vascular Robotics (OTC:CVRS) today touted that its CorPath robotic surgical platform was used in a first-in-human telerobotic intervention study in India. The Waltham, Mass.-based company touted that the study was the world’s first percutaneous coronary intervention conducted from a remote location outside of a catheterization lab. In the trial, five patients at India’s Apex Heart Institute underwent an elective PCI procedure from a distance of approximately 20 miles away, Corindus said. The procedures were performed by Apex Heart Institute chair and chief interventional cardiologist Dr. Tejas Patel f...
Source: Mass Device - December 6, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Featured Robotics Corindus Vascular Robotics Source Type: news

New Corindus Technology Successfully Used in Robotic-Assisted Coronary Intervention
The future of robotic-assisted surgery emerges ever closer with the news of Corindus Vascular Robotics's new CorPath GRX System being successfully used to enable robotic-assisted percutaneous coronary interventions (PCI) at the recent Transcatheter Cardiovascular Therapeutics 2018 (TCT) conference. The technology was used to perform the first live transmission of a hybrid chronic total occlusion PCI using both manual and robotic techniques to successfully treat a patient suffering from a complete coronary artery blockage. The CorPath System is described by the company as the first and only FDA-cleared medical device that c...
Source: MDDI - December 1, 2018 Category: Medical Devices Authors: Kristopher Sturgis Tags: Cardiovascular Source Type: news

ECG Educational Standards for Prehospital Providers
Conclusion As the role of evidence-based medicine becomes more prominent in the field of emergency medicine, a clear view of the current state of ECG education and platform from which to implement uniform standards becomes increasingly essential; especially as research expands into the prehospital setting. Further research into EMS education may identify both strengths and weaknesses in basic ECG interpretation appropriate for first responders. Implementing minimum ECG interpretation standards for EMS personnel nationwide is one potential option to ensure prehospital educational institutions stay responsive to current scie...
Source: JEMS Special Topics - November 27, 2018 Category: Emergency Medicine Authors: Jonathan Barney, BA, EMT, MS3 Tags: Training Exclusive Articles Cardiac & Resuscitation Source Type: news

Residual inflammation risk affects outcomes after percutaneous coronary intervention
(European Society of Cardiology) Patients who have persistently high levels of inflammation following percutaneous coronary intervention (PCI) for coronary artery disease are significantly more likely to die from any cause or to have a heart attack within a year, according to a study of 7,026 patients published in the European Heart Journal. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 19, 2018 Category: International Medicine & Public Health Source Type: news

What & #039;s Next for Bioresorbable Scaffolds?
Even with new data, the future of bioresorbable scaffolds remains in flux. At TCT 2018 in September, Reva Medical and Abbott Laboratories painted differing pictures with their respective bioresorbable scaffold studies. What now? Dr. Lukasz Koltowski from the Medical University of Warsaw in Warsaw, Poland, presented new data from Reva Medical's "Fantom STEMI" pilot study. The study showed procedural success and clinical utility of the Fantom bioresorbable scaffold in nine patients with acute ST-segment elevated myocardial infarction (“STEMI”) heart attacks. "Many heart attack patients are...
Source: MDDI - October 16, 2018 Category: Medical Devices Authors: Heather R. Johnson Tags: Business Cardiovascular Source Type: news

FDA clears 1st acute coronary artery perforation stent in 17 years
The FDA said today it approved Biotronik’s PK Papyrus covered coronary stent system intended to treat acute coronary artery perforations, touting it as the first such device to win clearance for that indication in 17 years. Coronary artery perforations can occur during percutaneous coronary intervention procedures and can create life-threatening conditions, the FDA said. In some such perforations, blood can leak through the tear and lead to a collection of blood in the sac surrounding the heart, putting a patient’s life at serious risk. The newly cleared PK Papyrus is a balloon-expandable covered coronary stent and del...
Source: Mass Device - September 14, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Stents Biotronik Source Type: news

FDA Approves First New Device for Heart Vessel Tears in 17 Years
  Cardiologists have a new tool for handling a rare but potentially life-threatening complication during percutaneous coronary intervention (PCI) procedures. FDA approved Biotronik's PK Papyrus Covered Coronary Stent System as a treatment for tears in the coronary arteries that can occur during heart vessel procedures. The PK Papyrus System is the first device FDA has approved for this indication in 17 years. The device has been CE marked for sale in Europe since 2013. "The PK Papyrus Covered Coronary Stent System provides healthcare providers with a new treatment option that...
Source: MDDI - September 14, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news

Acute myocardial infarction secondary to blunt chest trauma in motorcycle accident: a rare combination where percutaneous coronary intervention and intravascular imaging optimization are needed - Boi A, Sanna F, Rossi A, Loi B.
Blunt chest trauma is a common occurrence in vehicle accident. Cardiac injuries following nonpenetrating thoracic trauma have been reported. ST-elevation myocardial infarction (STEMI) due to coronary artery involvement is a rare but extremely serious condi... (Source: SafetyLit)
Source: SafetyLit - September 14, 2018 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Women are a FIFTH more likely to die after routine surgery for coronary heart disease
EXCLUSIVE Researchers from Keele University analysed 6.6 million patients over 10 years and found women who have a percutaneous coronary intervention are more at risk than men. (Source: the Mail online | Health)
Source: the Mail online | Health - September 10, 2018 Category: Consumer Health News Source Type: news

Medtronic launches one-month DAPT study for drug-eluting stent in U.S., Japan
Medtronic (NYSE:MDT) said today that it’s launching a study in the U.S. and Japan to evaluate dual antiplatelet therapy in high bleeding risk patients implanted with the Resolute Onyx drug-eluting stent during percutaneous coronary intervention. The company’s Onyx One Clear study is one of the first designed to assess the risk of cardiac death and stent thrombosis following DAPT interruption or discontinuation after one month with a next-gen drug-eluting stent, according to Medtronic. Get the full story at our sister site, Drug Delivery Business News. The post Medtronic launches one-month DAPT study for drug-eluting s...
Source: Mass Device - September 10, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Drug-Device Combinations Drug-Eluting Stents Pharmaceuticals Wall Street Beat Medtronic Source Type: news